SUBSCRIBE
SUBSCRIBE
News   Drug Development

Aradigm Corporation Completes Enrollment in Phase 2 Study of Inhaled Liposomal Ciprofloxacin for Bronchiectasis

October 14, 2008 | 
1 min read
HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) (“Aradigm”) today announced it completed enrollment in its Phase 2 clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis.
Clinical research Phase 2
MORE ON THIS TOPIC
Concept World kidney day, handcraft paper blue kidneys and stethoscope on yellow background. Copy space. Banner.
IgA nephropathy
Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data
June 5, 2026
 · 
2 min read
 · 
Tristan Manalac
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Lymphoma
ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drug
June 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Insights
Rethinking hair loss treatment
June 4, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Futuristic digital speedometer with glowing lines and red needle, representing fast acceleration and advanced automotive technology. vector eps10
Funding
NewLimit snags $435M after seeing age reversal in human liver cells
June 3, 2026
 · 
2 min read
 · 
Gabrielle Masson